Platelet Review July 2012 Thomas S. Kickler M.D. Johns Hopkins - - PowerPoint PPT Presentation

Platelet Review July 2012

Thomas S. Kickler M.D. Johns Hopkins University School of Medicine

Hemostasis

• Hemostasis is the process that leads to the

stopping of bleeding

• Hemostasis involves blood vessels, platelets,

plasma clotting proteins

• Primary Hemostasis is the initial response to

injury to a blood vessel involving platelets

• Secondary Hemostasis occurs to fortify primary

hemostasis thru the activation of clotting proteins to form a insoluble deposition of fibrin in and around platelets

Bleeding – Cut a Blood Vessel – What Happens ?

What is Going on in the Blood Vessel – a lot!

Platelet

PRIMARY HEMOSTASIS = PLATELET PLUG SECONDARY HEMOSTASIS = CLOTTING CASCADE

Overview of Hemostasis

Hemostasis- 2 components- Platelets, Clotting Proteins Both Occurring Simultaneously

Platelets Lead to Primary Hemostasis Clotting Cascade Leads to Secondary Hemostasis

Hemostasis

• Intricate system maintaining blood in fluid state

– Reacts to vascular injury to stop blood loss and seal vessel wall

• Involves platelets, clotting factors, endothelium, and

inhibitory/control mechanisms – Highly developed system of checks and balances Bleeding Thrombosis Normal Hemostasis

Absence of overt bleeding/thrombosis

Platelets are typically 1-2 micron The normal PLT count is 150-350,000/ul One large one above shows how granular they appear.

A scanning electron micrograph

• f normal platelets

Really are fragments of megakaryocyte cytoplasm

Platelet- Number, Lifespan and Kinetics

• Normal platelet concentration is 150,000-

350,000/ ul

• Platelets are produced in the bone marrow by

megakaryocytes and released into the circulation

• They circulate in the blood for about 10 days after

release from the marrow

• About 1/3 of all the body’s platelet mass is stored

in the spleen

Megakaryocytes produce platelets in the marrow, stimulated by thrombopoietin

Normal Megakaryocyte

Platelets are released from megakaryocytes , this shows this process in vitro culture

Hematopoiesis

Stem cell T cells B cells lymphocytes neutrophil RBC monocyte platelets

Stages of platelet development

Stem cell BFU-Mk CFU-Mk Immature Mk Mature Mk Platelet shedding

commitment Terminal differentiation

All stages are driven by thrombopoietin

Thrombopoietin (TPO)

• Growth factor produced in liver
• Increases production of megakaryocytes
• Essential for stem cells

control +TPO

1 2 3 4 5 6 1 2 3 4 5 6 7

Days Platelets ( x 10

6/mm3)

TPO Effect on Normal Mice

control +TPO Mouse bone marrow

TPO regulation

• Constitutive (constant) production
• Level depends on binding sites on platelets and

megakaryocytes

Thrombopoietin Regulation (Sponge theory)

PLT

TPO MPL

PLT

As Platelet Count Increases, serve as a sponge , having less available to stimulate Megakaryocytes

Primary Hemostasis

Adhesion Aggregation Secretion

Adhesion occurs within 1-3 seconds after injury

As adhesion occurs, platelets release ADP and Thromboxane (TxA2) , these help recruit other platelets into the platelet plug and as secondary hemostasis gets started thombin is generated, causing more platelet stimulation and conversion of fibrinogen to fibrin

3-7 minutes for entire process to occur-”The Bleeding Time”

Activated platelets Note pseudopodia and how platelets aggregating to each other

A scanning EM of a clot with platelets, RBCs trapped in mesh of developing fibrin

Fibrinogen

Fibrin – polymerized remains of fibrinogen Think of fibrin as strands of protein that holds the platelets together Thrombin transforms fibrinogen to a mesh of fibrin strands EM of fibrinogen that has been treated with Thombin

Remember Platelets act in Concert with Fibrin Formation to Form a Firm Clot

Summary of Platelet Processess

Bleeding Time Normal 3-7 minutes Prolonged in platelet function abnormalities

Testing for Abnormal Platelet Function

Bleeding Time Aggregometry

normal < 7-8min An abnormal response to ADP

• ptical density

time

A bleeding time that did not

Bleeding – Cut a Blood Vessel – What Happens ?

The endothelium is “antagonistic” to platelets under normal conditions

The Endothelium Prevents Excess Platelet Function In Vivo

Vascular Endothelium Function

Tissue factor pathway inhibitor Thrombomodulin Tissue plasminogen activator Heparan sulfate proteoglycans Tissue factor Anticoagulant- Inhibits coagulation extrinsic pathway Anticoagulant- Inhibits coagulation by activating protein C system Anticoagulant- Inhibits coagulation by activating fibrinolysis Anticoagulant- Inhibits coagulation by activating antithrombin Procoagulant- Inflammatory cytokines (IL-1, TNF) induce expression

Vascular Endothelium Function

Prostacyclin Thromboxane A2 ELAMs, ICAMs von Willebrand factor Vasodilation, inhibition of platelet aggregation From platelets, muscular arteries constrict Cytokines induce synthesis to promote leukocyte adhesion Promote platelet-collagen adhesion to exposed sub-endothelium

Thombocytopenia

• > 100,000/ul no excessive bleeding, even

with major surgery

• 50-100,000 may bleed longer than normal

with severe trauma

• 20-50,000 bleed with minor trauma
• < 20,000 may have spontaneous

hemorrhage

Petechiae- subcutaneous bleeding develops when the

platelet counts falls below 20- 50, 000/ul

Nachman R and Rafii S. N Engl J Med 2008;359:1261-1270

Adherens Junction at the Postcapillary Venular Bed

Nachman R and Rafii S. N Engl J Med 2008;359:1261-1270

Bleeding in Patients with Thrombocytopenia through Disassembly of the Adherens Junction

Causes of Thrombocytopenia

• Decreased production: marrow hypoplasia,

leukemia, toxins, chemotherapy

• Increased Destruction: antibodies to platelets,

activation of coagulation cascade resulting in PLT consumption

• Platelet Sequestration: 1/3 of platelets are

normally stored in the spleen, if enlarges more platelets are stored and patient becomes thrombocytopenic

Decreased Production

Decreased production: marrow hypoplasia, leukemia, toxins, chemotherapy

No straightforward method to assess platelet production , unlike RBCs & Retic Count

Severe thrombocytopenia in Autoimmune thrombocytopenia Blood smear shows no platelets Isotope labeled platelets are destroyed in the spleen, in presence of antibody

Pathophysiology of Autoimmune Thrombocytopenia

An example of a common consumptive thrombocytopenia

Autoantibodies are formed against the platelet glycoprotein receptor IIb-IIIa, and are destroyed in the Reticuloendothelial system

Panel A , patient without increased Megakaryocytes, versus patients with increased megakaryocytes

IPF(%) Ref: 3%

H-IPF(%) Ref: 1%

Fluorescence intensity

(Linear )

FSC (Cell size)

(Logarithm )

IPF#

(x109/L)

PLT-X

(ch)

Overview of Immature Platelet Fraction Percentage (IPF%) Measurement & Some Examples normal ITP Nadir after Chemo Recovery from Chemo

Thrombocytosis

Seen in myeloproliferative disorders, chronic infection, iron deficiencies, malignant tumors

Platelets Role in Thrombosis

• Coronary or

cerebrovascular thrombosis is multifactorial

• Genes – lipids
• Society – diet,

exercise, smoking

Triggers of Thrombosis Artery v Vein

VEIN – CLOTTING PROTEINS ROLE CERTAIN ARTERY – PLATELETS ROLE CERTAIN

Summary

• Describe the major physiologic functions
• f platelets
• Describe the major platelet agonists
• Describe the ligands responsible for

adhesion and aggregation

• Describe the pathophysiology of

thrombocytopenia

Hemostasis- Summary